The United States Food and Drug Administration issued a partial clinical hold on new trial enrollment for<unk>  on October 9, 2013 due to an increased number of blood clots observed in patients taking the drug. The EPIC trial was later canceled on October 18. Subsequent studies of 449 patients treated during 4 years with<unk>  for chronic phase chronic myelogenous leukemia found the following adverse reactions. 150 Patients experienced cardiac vascular (21% of patients), peripheral vascular (12%), and cerebrovascular (9%) arterial occlusive events. Venous thromboembolic events occurred in 6% of patients. The most common all-grade adverse events included hypertension (69%), rash (63%), abdominal pain (48%), fatigue (47%), headache (43%), arterial ischemia (42%), dry skin (42%), constipation (41%), arthralgia (32%), nausea (28%), pyrexia (26%), peripheral neuropathy (24%), myalgia (24%), pain in extremity (23%), back pain (21%), and diarrhea (20%). In addition, there have been reported cases of the posterior reversible encephalopathy syndrome.
Ponatinib
Neratinib
Tucatinib
Dasatinib
Fostamatinib
Imatinib
Lapatinib
Pemigatinib